|
|
Article: Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind™ to the European Market.
- Article from:
- Biotech Week
- Article date:
- November 11, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Pulmo BioTech Inc. (OTC Bulletin Board: PLMO; Frankfort Borse: PBO) has announced that it will ultimately receive at least $3.3 million pursuant to the license agreement contemplated by the previously announced non-binding letter of intent with Biotechnology Consulting Poland Sp. z.o.o. with respect to its Pulmonary Vascular Diagnostic Product Candidate PulmoBind™ development work, clinical trials and ultimately, commercialization in the European market (see also Biotechnology).
"We are pleased that the relationship with Biotechnology Consulting Poland to be finalized in a license agreement expected before the end of 2009 will allow Pulmo BioTech to bring ...